Editorial & Advertiser disclosure

Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Headlines

Roche to acquire liver drug developer 89bio for up to $3.5 billion

Q: What is the value of Roche's acquisition of 89bio?

Roche's acquisition of U.S. biotech firm 89bio is valued at about $2.4 billion, with the potential to reach up to $3.5 billion including a non-tradeable contingent value right.

Q: What diseases does Roche aim to target with this acquisition?

Roche aims to strengthen its development pipeline for liver and cardiometabolic diseases through this acquisition.

Q: Who reported on Roche's acquisition of 89bio?

The article was reported by Ludwig Burger and edited by Kim Coghill.

Published by Global Banking & Finance Review

Posted on September 18, 2025

1 min read

· Last updated: January 21, 2026

Add as preferred source on Google

Roche to acquire liver drug developer 89bio for up to $3.5 billion

innovation investment

Global Banking & Finance Awards 2026 — Call for Entries

FRANKFURT (Reuters) -Roche said on Thursday it agreed to acquire U.S. biotech firm 89bio <ETNB.O for up to $3.5 billion to strengthen its development pipeline on liver and cardiometabolic disease

Roche to Acquire 89bio for Up to $3.5 Billion in Liver Drug Deal

FRANKFURT (Reuters) -Roche said on Thursday it agreed to acquire U.S. biotech firm 89bio <ETNB.O for up to $3.5 billion to strengthen its development pipeline on liver and cardiometabolic disease treatments.

In a statement, the Swiss drugmaker said the deal was worth about $2.4 billion, or up to $3.5 billion when including a non-tradeable contingent value right.

(Reporting by Ludwig Burger; Editing by Kim Coghill)

Key Takeaways

Roche to acquire 89bio for up to $3.5 billion.
The deal strengthens Roche's liver and cardiometabolic pipeline.
Initial deal valued at $2.4 billion, with potential for more.
Includes a non-tradeable contingent value right.
Roche aims to enhance its biotech capabilities.

Frequently Asked Questions

What is the value of Roche's acquisition of 89bio?

Roche's acquisition of U.S. biotech firm 89bio is valued at about $2.4 billion, with the potential to reach up to $3.5 billion including a non-tradeable contingent value right.

What diseases does Roche aim to target with this acquisition?

Roche aims to strengthen its development pipeline for liver and cardiometabolic diseases through this acquisition.

Who reported on Roche's acquisition of 89bio?

The article was reported by Ludwig Burger and edited by Kim Coghill.

More from Headlines

Explore more articles in the Headlines category

UK's Starmer and Trump discuss 'urgent need' to restore shipping in Strait of Hormuz

Pope Leo says those who wage war are thieves stealing away our peaceful future

King Charles relieved Trump and first lady unharmed after shooting

Northern Ireland police investigate car explosion as attempted murder

UK says cooperating closely with US on security ahead of King Charles' visit

Israeli attacks kill at least four Palestinians in Gaza, medics say

Six passengers injured evacuating from Swiss Air flight in India, Economic Times says

Trump removed from White House correspondents dinner as attendees take cover

Car explodes outside police station in Northern Ireland, Belfast Telegraph reports

US-Iran peace hopes fade as Trump scraps talks

Ukraine marks 40th anniversary of Chornobyl disaster under cloud of war

Russia's parliamentary speaker visits Pyongyang, KCNA says

View All Headlines Posts

Roche to acquire liver drug developer 89bio for up to $3.5 billion

Roche to Acquire 89bio for Up to $3.5 Billion in Liver Drug Deal

Key Takeaways

Frequently Asked Questions

Tags

Related Articles

Buckingham Palace says King Charles' trip to the US to go ahead

Italy to extradite suspected Chinese hacker wanted by US authorities, says source

Soccer-Chelsea reach FA Cup final with 1-0 win over Leeds

Netanyahu's biggest rivals join forces for Israel's next election

Israel issues evacuation warning for seven Lebanese towns beyond 'buffer zone'

Athletics-Kenya's Sawe shatters elusive two-hour marathon barrier to win in London

More from Headlines